H.C. Wainwright analyst Oren Livnat views the selloff in Pacira Pharmaceuticals (PCRX) today after the company preannounced "another Exparel beat" as unwarranted. Pacira continued its "impressive streak of beats," Livnat tells investors in a research note. The analyst attributes the pullback to both "selling-the-news" as investors now see the next event being a likely approval of competing HTX-011 from Heron Therapeutics (HRTX) on its April 30 FDA action date plus the new HTX-011 "opioid-sparing" data released today. He sees the pullback in Pacira as a buying opportunity since he expects its momentum to continue into 2019. Livnat keeps a Buy rating on Pacira with a $60 price target.